The Impact of Methylene Blue on the Quality of Recovery in Patients Undergoing Hemorrhoidectomy
Launched by QILU HOSPITAL OF SHANDONG UNIVERSITY · Dec 18, 2024
Trial Information
Current as of July 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effects of a medication called methylene blue on the recovery quality of patients who are having surgery for hemorrhoids, a common condition that can cause pain and discomfort. The research aims to see if injecting methylene blue along with another pain relief medication can help improve how patients feel after the surgery. The quality of recovery will be measured using a questionnaire that looks at different aspects of health and comfort, such as pain levels and emotional well-being.
To be eligible for this study, participants must be between 18 and 65 years old and diagnosed with significant hemorrhoids that require surgery. They should not have certain medical conditions or be taking specific medications that could interfere with the study. Participants can expect to receive standard spinal anesthesia for their surgery, and their recovery will be monitored closely over several days and months. This trial is currently recruiting and aims to gather valuable information to improve postoperative care for patients undergoing hemorrhoid surgery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosed with mixed hemorrhoids, grade III/ IV hemorrhoids (Goligher's classification), and underwent hemorrhoidectomy under spinal anesthesia; and
- • Aged between 18 and 65 years; and
- • ASA I or II.
- Exclusion Criteria:
- • Patients who experienced any ill-effects from previous use of MB or other medications in the protocol (ketorolac, ropivacaine); or
- • Patients with diabetes; or
- • Alcohol or other addictive drug dependence; or
- • Illiteracy, combined with mental system or severe mental illness that prevented completion of the assessment; or
- • Patients who are pregnant or breast-feeding; or
- • Aspirin and analgesic drugs taken within 2 weeks before surgery; or
- • Patients taking selective serotonin reuptake inhibitors (SSRIs); or
- • Concurrent additional anorectal diseases (e.g., perianal abscess, anal fistula, fissures, anal incontinence); or
- • Patients who are participating in other clinical trials and have not reached the endpoint.
About Qilu Hospital Of Shandong University
Qilu Hospital of Shandong University is a leading medical institution dedicated to advancing healthcare through innovative clinical research and patient-centered care. Affiliated with Shandong University, the hospital integrates clinical practice with education and research, fostering an environment that promotes scientific discovery and the development of new therapies. With a commitment to high standards of clinical excellence and ethical research practices, Qilu Hospital plays a pivotal role in enhancing patient outcomes and contributing to the global medical community through a diverse range of clinical trials and studies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Jinan, Shandong, China
Weifang, Shandong, China
Heze, Shandong, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported